Industrial-Scale Palladium-Catalyzed Coupling of Aryl Halides and Amines -A Personal Account

Total Page:16

File Type:pdf, Size:1020Kb

Industrial-Scale Palladium-Catalyzed Coupling of Aryl Halides and Amines -A Personal Account REVIEW DOI: 10.1002/adsc.200505158 Industrial-Scale Palladium-Catalyzed Couplingof Aryl Halides and Amines – A Personal Account Stephen L. Buchwald,a Christelle Mauger,b, e Gerard Mignani,b,* Ulrich Scholzc, d,* a Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA Fax: (þ 1)-617-253-3297, e-mail: [email protected] b Rhodia, Centre de Recherche de Lyon, 85 rue des Fre`res Perret, BP62, 69192 Saint-Fons Cedex, France Fax: (þ 33)-4-72-89-68-55, e-mail: [email protected] c Lanxess Deutschland GmbH, Fine Chemicals Research & Development, 51368 Leverkusen, Germany d Current address: Boehringer Ingelheim Pharma GmbH & Co. KG, Dept. Process Development, 55216 Ingelheim am Rhein, Germany E-mail: [email protected] e Current address: Reckitt Benckiser, Dauson Lane, Hull HU8 7DS, United Kingdom E-mail: [email protected] Received: April 18, 2005; Accepted: July12, 2005 Abstract: The palladium-catalyzed coupling of amines 4 The Preparation of Arylpiperazines as a Model and aryl halides or aryl alcohol derivatives has ma- Process for the Scale-Up of Palladium-Catalyzed tured from an exotic small-scale transformation into Aromatic Amination a verygeneral, efficient and robust reaction during 5 Synthesis of Industrially Important Diarylamines the last ten years. This article reports several applica- byC ÀN coupling tions of this method from an industrial vantage point, 6 Synthesis of the Dialkylphosphinobiaryl Ligands including ligand synthesis, synthesis of arylpipera- 7 Synthesis of Chlorodicyclohexylphosphine zines, arylhydrazines and diarylamines. Much empha- 8 Synthesis of Ligands A and C sis in placed on issues of scale-up and safetyto under- 9 Synthesis of Ligand B line the potential of CÀN couplings as solutions for in- 10 Removal/Recycling of Palladium after the Reac- dustrial-scale synthetic problems. tion 11 Conclusions and Prospects for Future Work 1 Introduction 2 Motivation: Technologygives an Edge 3 The Synthesis of Arylhydrazones and their use as Keywords: amination; anilines; CÀN cross-coupling; Synthetic Intermediates homogeneous catalysis; palladium; phosphane ligands 1 Introduction rials, polymers, liquid crystals and xerographic materi- als.[2] The development of a new, general methodologyfor the Over the first ten years since its development, small- formation of aromatic carbon-nitrogen bonds is of great scale applications of the palladium-catalyzed aromatic significance in manyareas of organic synthesis. As the amination have appeared in publications from academ- Heck, Suzuki–Miyaura, Stille, Kumada and Negishi pro- ic, medicinal and process chemistrylaboratories. This cedures have revolutionized the waywe construct sp2C– method is able to connect highlyfunctionalized compo- sp2C bonds,[1] the palladium-catalyzed aromatic amina- nents and is compatible with a wide varietyof functional tion has the potential to modifyanalogouslyour ap- groups. This generalitymakes it well-suited for the con- proach to the synthesis of aniline derivatives. Aromatic struction of a bodyof amine analogues from a common carbon-nitrogen bonds are structural constituents for intermediate. The versatilityand applicabilityof the the preparation of compounds of interest to those method has been thoroughlydocumented in two recent in the pharmaceutical and agrochemical industries. reviews.[3] In addition, compounds with this motif are impor- tant for the preparation of new ligands, electronic mate- Adv. Synth. Catal. 2006, 348, 23 – 39 2006 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 23 REVIEW Stephen L. Buchwald et al. Stephen L. Buchwald was Christelle C. Mauger was born (1955), raised and re- born in Saint-Loˆ in Nor- ceived his precollege edu- mandy(France) in 1974. cation in Bloomington, In- She completed her under- diana. He received his graduate degree at the Sc. B. degree, Magna Cum Universityof Caen and ob- Laude, in chemistry, from tained her Ph. D. degree in Brown Universityin 1977. organic chemistryin 2000 During his undergraduate under the guidance of Dr years he worked in the lab- Serge Masson (Labora- oratories of Professors toire de Chimie Mole´cu- Kathlyn A. Parker and laire et Thioorganique, David E. Cane at Brown Universityand Professor Caen, France). She then moved to Huddersfield Gilbert Stork at Columbia University. He entered (England) to join Avecia Pharmaceuticals for an in- Harvard Universityas a National Science Foundation dustrial postdoctoral position. She worked on the Predoctoral Fellow in 1977 and received his Ph. D. in rapid development of new routes to pharmaceutical 1982. His thesis work, under the supervision of Pro- intermediates and on the “CaTHy” catalytic transfer fessor JeremyR. Knowles, concerned the mechanism hydrogenation reaction. In 2001 she accepted a post- of phosphoryl transfer reactions in chemistry and bio- doctoral position granted byRhodia Organic at the chemistry. In early 1982 he took up a position as a Universityof Poitiers (Laboratoire de Catalyseen Myron A. Bantrell postdoctoral fellow at the Califor- Chimie Organique, France) where she worked in nia Institute of Technologywhere he worked in the the fields of fluorine chemistry. In 2002, she joined laboratoryof Professor Robert H. Grubbs. His Rhodia Recherches (Lyon Research Centre) as a re- work at Caltech concerned the studyof titanocene search engineer in the Process Research Group. Her methylenes as reagents in organic synthesis. During main area of activities was the development of pharma- this time he was also involved in work on the mech- ceutical intermediates using organometallic catalysis anism of the Ziegler–Natta polymerization. In 1984 and aromatic bond forming reactions (ABF). In Janu- he began as an assistant professor of chemistryat ary2006, she moved to the Reckitt Benckiser scientific the Massachusetts Institute of Technology. He was services department in Kingston-upon-Hull (UK). promoted to the rank of associate professor in 1989 and to Professor in 1993. He was named the Camille Ge´rard Mignani studied Dreyfus Professor of Chemistry in January of 1997. chemistryin Orsayand During his time at MIT he has received numerous Rennes Universities where honors including the Harold Edgerton FacultyAch- he received his Ph. D. ievement Award of MIT, an Arthur C. Cope Scholar (Docteur Inge´nieur) in Award, the 2000 Award in Organometallic Chemistry 1980 and his “The`se dE- from the American Chemical Society, a MERIT tat” in 1982 in the field of award from the National Institutes of Health, the organometallic chemistry Bristol-Myers Squibb Distinguished Achievement and homogeneous cataly- Award in Organic Synthesis (2005), the CAS Spot- sis especiallyin steroid light Award (2005) and the American Chemical Soci- chemistry(Rhoˆ ne-Poulenc etyAward for Creative Work in Synthetic Organic Grant) in Professor Da- Chemistry(2006). In 2000, he was elected as a mem- bards group. He joined the Rhoˆ ne-Poulenc Research ber in the American Academyof Arts and Sciences. group in Lyon in 1980 where he developed new proc- He has been a named lecturer at numerous universi- esses in organic and terpene chemistryand in homo- ties. He is the coauthor of 245 published or accepted geneous and heterogeneous catalysis. Thereafter he papers and 30 issued patents. He serves as a consul- performed postdoctoral research with Professor D. tant to Amgen, Merck, InfinityPharmaeuticals, Rho- Seyferth at the Massachusetts Institute of Technology dia Pharmaceutical Solutions, Lanxess, Englehard (Cambridge, U. S. A.) on ceramic precursors and or- and Collegium Pharmaceuticals. He and Eric Jacob- ganosilicon chemistry. He came back to Rhoˆ ne-Pou- sen have co-taught a short course on Organometallic lenc research where he developed new ceramic pre- Chemistryin Organic Synthesis at over 35 companies cursors, new non-linear optic derivatives, polymers, in the U. S. A. and in Europe. and homogeneous catalysis processes. He spent ten years as a Group Leader in Silicon Chemistry. His re- search interests were the poly-functionalization of 24 asc.wiley-vch.de 2006 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Adv. Synth. Catal. 2006, 348,23–39 Industrial-Scale Palladium-Catalyzed Coupling of Aryl Halides and Amines REVIEW polysiloxanes, new organometallic catalysis for orga- chemistryand received his diploma degree in Profes- nosilicon applications and the functionalization of sor E. Winterfeldts research group in 1996 on the mineral charges. Now, his research interests are the synthesis of unsymmetrical pyrazines. He stayed in new processes and scale-up in organic chemistry, or- Professor Winterfeldts group and spent the subse- ganometallic catalysis (homogeneous and heteroge- quent three years on the elaboration of bile acids as neous) and new methodologyin chemistrysynthesis. potential building blocks for the synthesis of cepha- He received the “Prix de la Recherche” in 1995, in lostatin analogues. After graduation he continued as 2001 “Prix RHODIA Group” and in 2004 “Prix Cen- a teaching assistant at Hannover Universityto finally tre de Recherches-RHODIA”. join the Central Research Department for homoge- neous catalysis of Bayer AG at the end of 1999. In Ulrich Scholz started his 2002, he moved to the process development depart- studies in chemistryin ment of the Bayer Chemicals Company, now Lanxess 1990 at the Universityof – Fine Chemicals as a project manager of the Special- Hannover, Germany. In ityChemicals Department. Since 2001, he also head- 1993, he joined
Recommended publications
  • Totalcare Medicaid 2017 Q2 GB
    Preferred Drug List Molina Healthcare of New York, Inc. 2017 *Molina mandates the use of generic drugs, if available. Brand names listed are for reference only. THIS LIST IS SUBJECT TO CHANGE. You can get more information and updates to this document on our website at www.molinahealthcare.com MCD_CO_ESIPREFDRUGQ3_0817_08/27/2017 6025633NY0417 Table of Contents Anti - Infectives....................................................................................................................................................3 Antineoplastic / Immunosuppressant Drugs ......................................................................................................12 Autonomic / Cns Drugs, Neurology / Psych ......................................................................................................17 Cardiovascular, Hypertension / Lipids...............................................................................................................34 Dermatologicals/Topical Therapy......................................................................................................................41 Diagnostics / Miscellaneous Agents ..................................................................................................................56 Ear, Nose / Throat Medications..........................................................................................................................64 Endocrine/Diabetes ............................................................................................................................................66
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Pharmacology of Ophthalmic Agents
    Ophthalmic Pharmacology Richard Alan Lewis M.D., M.S., PHARMACOLOGY FOPS PHARMACOKINETICS OF Professor, Departments of Ophthalmology, • The study of the absorption, OPHTHALMIC Medicine, Pediatrics, and Molecular distribution, metabolism, AGENTS and Human Genetics and excretion of a drug or and the National School of Tropical agent Introduction and Review Medicine Houston, Texas PHARMACOKINETICS Factors Affecting Drug Penetration Factors Affecting Drug Penetration into Ocular Tissues • A drug can be delivered to ocular tissue: into Ocular Tissues – Locally: • Drug concentration and solubility: The higher the concentration the better the penetration, • Surfactants: The preservatives in ocular • Eye drop but limited by reflex tearing. preparations alter cell membrane in the cornea • Ointment and increase drug permeability, e.g., • Viscosity: Addition of methylcellulose and benzalkonium and thiomersal • Periocular injection polyvinyl alcohol increases drug penetration by • pH: The normal tear pH is 7.4; if the drug pH is • Intraocular injection increasing the contact time with the cornea and altering corneal epithelium. much different, it will cause reflex tearing. – Systemically: • Lipid solubility: Because of the lipid rich • Drug tonicity: When an alkaloid drug is put in • Orally environment of the epithelial cell membranes, relatively alkaloid medium, the proportion of the uncharged form will increase, thus more • IM the higher lipid solubility, the more the penetration. • IV penetration. FLUORESCEIN FLUORESCEIN Chemistry Dosage ● C20H1205, brown crystal ● Adults: 500-750 mg IV ● M.W. 322.3 e.g., 3 cc 25% solution ● Peak absorption 485-500 nm. 5 cc 10% solution ● Peak emission 520-530 nm. ● Children: 1.5-2.5 mg/kg IV Richard Alan Lewis, M.D., M.S.
    [Show full text]
  • Use of Sildenafil in Patients with Cardiovascular Disease
    Arq Bras Cardiol GuimarãesReview et al volume 73, (nº6), 1999 Sildenafil in patients with cardiovascular disease Use of Sildenafil in Patients with Cardiovascular Disease Armênio Costa Guimarães, Marcus Vinícius Bolívar Malachias, Otávio Rizzi Coelho, Emílio Cesar Zilli, Rafael Leite Luna Introduction of phosphodiesterase inhibitors. The erectile action of sildenafil combines increase in arterial flow with reduction Erectile dysfunction, formerly called impotence, is the in the venous flow of cavernous body of penis. Sildenafil inability of the male to achieve or maintain penile erection and leads to relaxation of smooth muscle of penile arteries and thus engage in coitus1. It is common among patients with trabeculae surrounding the sinusoidal spaces, resulting in cardiovascular diseases or their risk factors. This dysfunc- a greater engorgement of cavernous body. The trabeculae tion occurs mainly among individuals with coronary artery of engorged sinusoidal spaces compress the penile disease, after episodes of acute ischemic syndrome, hyper- venules against the tunica albuginea, reducing venous tensive patients underpharmacologic treatment, and among flow, contributing to maintenance of engorgement of patients with heart failure. In approximately 85% of these ca- cavernous body8. Relaxation of this smooth muscle ses, the fear of a cardiac event during coitus constitutes an results from a decrease in intracellular calcium mediated important factor for erectile dysfunction 2-4. by accumulation of the second messenger, the cyclic Discovery of sildenafil citrate has represented a great de- guanosine monophosphate (cGMP), whose production velopment in the treatment of erectile dysfunction; it may results from activation of guanyl cyclase by nitric oxide benefit, among many others, those patients with cardiovascu- produced by the stimulus of endothelial cells generated lar diseases or with their risk factors 5.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,894,970 B2 Tomczuk Et Al
    US008894970B2 (12) United States Patent (10) Patent No.: US 8,894,970 B2 Tomczuk et al. (45) Date of Patent: Nov. 25, 2014 (54) ARGINASE INHIBITORS AND METHODS OF 546/184, 133, 138, 139, 152; 548/560; USE THEREOF 540/484 See application file for complete search history. (75) Inventors: Bruce Edward Tomczuk, Collegeville, PA (US); Gary Lee Olson, (56) References Cited Mountainside, NJ (US); Richard Scott Pottorf, Belle Mead, NJ (US); Lijuan U.S. PATENT DOCUMENTS Jane Wang, Wildwood, MO (US); Bhask Rao Nall h 4.483,853. A 11/1984 Collins et al. naskara Kao Nalagancnu, 5,792,769 A * 8/1998 Lu et al. ...... 514,252.12 Hillsborough, NJ (US); Yanqun Zhang, 5,891,909 A * 4/1999 Soll et al. ...................... 514/517 East Brunswick, NJ (US) 6,037,356 A * 3/2000 Lu et al. ...... ... 514,349 6,133,315 A * 10/2000 Lu et al. ...... 514/517 6,204.263 B1* 3/2001 Lu et al. ...... 514,235.8 (73) Assignee: Corridor Pharmaceuticals, Inc., 6,225,302 B1* 5/2001 Lu et al. ......... ... 514, 183 Towson, MD (US) 6,235,778 B1* 5/2001 Tomczuk et al. 514/517 6,245,763 B1* 6/2001 Lu et al. ......... ... 514,247 (*) Notice: Subject to any disclaimer, the term of this 6,281.206 B1 : 8/2001 Lu et al. ...... ... 514, 183 patent is extended or adjusted under 35 6,326,492 B1* 12/2001 Wang et al. ..................... 544, 63 6,344,466 B2 * 2/2002 Soll et al. ....... ... 514,331 U.S.C. 154(b) by 356 days.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub
    US 2002O187986A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub. Date: Dec. 12, 2002 (54) OPHTHALMIC FORMULATION WHICH Related U.S. Application Data MODULATES DILATION (62) Division of application No. 09/710,758, filed on Nov. (76) Inventor: Gerald Horn, Deerfield, IL (US) 8, 2000, now Pat. No. 6,420,407. Publication Classification Correspondence Address: Bell, Boyd & Lloyd LLC (51) Int. Cl." .................. A61K 31/517; A61K 31/4745; P.O. BOX 1135 A61K 31/4168; A61K 31/4164 Chicago, IL 60690 (US) (52) U.S. Cl. ..................... 514/252.17; 514/283; 514/401 (57) ABSTRACT (21) Appl. No.: 10/165,459 An ophthalmic formulation is disclosed which reduces dila (22) Filed: Jun. 7, 2002 tion in dim light and reduces redness. US 2002/0187986 A1 Dec. 12, 2002 OPHTHALMC FORMULATION WHICH 0007 A formulation for optimizing pupil size in extreme MODULATES DILATION lighting conditions is disclosed. The formulation is prefer ably a Solution of the type used in an artificial tear formu FIELD OF THE INVENTION lation having dissolved therein a therapeutically effective 0001. The present invention relates to a composition amount of a compound characterized by its ability to reduce formulated and administered to a human eye to reduce dilation of the eye, particularly in dim light. The compound dilation and redness. generally interferes with a natural biochemical reaction which results in the stimulation of the dilator muscles of the BACKGROUND OF THE INVENTION eye. The formulation is preferably further comprised of a compound which reduces eye redness, e.g.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • General Pharmacology
    GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,333,354 B1 Schudt (45) Date of Patent: Dec
    USOO6333354B1 (12) United States Patent (10) Patent No.: US 6,333,354 B1 Schudt (45) Date of Patent: Dec. 25, 2001 (54) SYNERGISTIC COMBINATION OF PDE Buerke et al.: “Synergistic platelet inhibitory effect of the INHIBITORS AND ADENYLATE CYCLASE phosphodiesterase inhibitor piroximone and iloprost: Pros AGONSTS OR GUANYL CYCLYSE taglandins in the Cardiovascular System, 1992, 37/suppl. AGONSTS (71–77).* (75) Inventor: Christian Schudt, Constance (DE) O'Grady et al. “A chemically stable analot 9-beta methyl carbacyclin with Similar effects to epoprostenol proStacyclin (73) Assignee: Byk Gulden Lomberg Chemische prostaglandin in I-2 in man” Br J Clin Pharmacol, 18(6). Fabrik GmbH, Constance (DE) 1984 (921-934).* (*) Notice: Subject to any disclaimer, the term of this Crutchley et al. “Effects of Prostacyclin Analogs on the patent is extended or adjusted under 35 Synthesis of Tissue Factor, Tumor Necrosis Facotr-alpha U.S.C. 154(b) by 0 days. and Interleukin-1beta in Human Monocytic THP-1 Cells”, J Pharmacol and Experimental Therapeutics, 271 (1). 1994. (21) Appl. No.: 09/367,850 446-451. (22) PCT Filed: Feb. 24, 1998 Crutchley et al. “Prostacyclin Analogues Inhibit Tissue (86) PCT No.: PCT/EP98/O1047 Factor Expression in the Human Monocytic Cell Line THP-1 Via a Cyclic AMP-Dependent Mechanism” Arterio S371 Date: Aug. 27, 1999 scler. Thromb, 12(6), 1992. 664-670.* S 102(e) Date: Aug. 27, 1999 Turner et al., Br. J. Pharmacol., “Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the (87) PCT Pub. No.: WO98/37894 anaesthetized guinea-pig", (1994), 111, pp.
    [Show full text]
  • Mechanism of Drug-Induced Qt Interval Prolongation
    ABSTRACT Torsades de pointes (TdP) is a polymorphic ventricular tachycardia characterized by a distinctive pattern of undulating QRS complexes that twist around the isoelectric line. TdP is usually self-terminating or can subsequently degenerate into ventricular fibrillation, syncope, and sudden death. TdP has been associated with QT interval prolongation of the electrocardiogram; therefore, the QT interval has come to be recognized as a surrogate marker for the risk of TdP. International guidelines have been developed to harmonize both the preclinical and clinical studies for the evaluation of drug-induced TdP. However, currently preclinical in vitro and in vivo methods as well as biomarkers for proarrhythmias have been imperfect in predicting drug-induced TdP in humans. It is clear that relevant biomarkers together with appropriate models are needed to assess the arrhythmic risk of new chemical entities. The goal of the present dissertation is to create rabbit with myocardial failing heart as an in vivo animal model to predict TdP in humans and to determine mechanism(s) underlying TdP in this model. Electrocardiograms were recorded from bipolar transthoracic leads in 7 conscious healthy rabbits previously trained to rest quietly in slings. The RR and QT relationship, ii QT=2.4RR0.72 (r2=0.79, p < 0.001) was obtained by slowed the heart rate with 2.0 mg/kg zatebradine, and the algorithm for removing effect of heart rate on QT is QTc = QT/(RR)0.72. QTc lengthened significantly in all conscious rabbits given intravenous cisapride, dofetilide or haloperidol (p < 0.05), and QTc did not change with DMSO (vehicle control), propranolol or enalaprilat.
    [Show full text]